HIV pathogenesis: The host

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 9, 2012, Pages

  Lackner, A A ^a   Lederman, Michael M ^b   Rodriguez, Benigno ^b  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; CHLOROQUINE; HYDROXYCHLOROQUINE; INTERLEUKIN 6; RIFAXIMIN; TUMOR NECROSIS FACTOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INTESTINE FUNCTION; LYMPHOID TISSUE; MICROBIAL TRANSLOCATION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; MUCOSAL IMMUNE SYSTEM; NONHUMAN; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS PATHOGENESIS; VIRUS REPLICATION; ANIMAL; BACTERIAL TRANSLOCATION; CELLULAR IMMUNITY; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGY; INNATE IMMUNITY; MACACA; MUCOSAL IMMUNITY; PATHOGENICITY; PHYSIOLOGY; PRIMATE; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

CERCOPITHECUS AETHIOPS; HUMAN IMMUNODEFICIENCY VIRUS; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTI-HIV AGENTS; BACTERIAL TRANSLOCATION; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HIV; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNITY, CELLULAR; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; MACACA; PRIMATES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84870756561     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a007005     Document Type: Article

References (209)

1. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. 2005. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 79: 12164-12172.
2. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, BergerEA. 1996. CC CKR5: A RANTES, MIP-1a, MIP-1b receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
3. Antiretroviral Therapy Cohort Collaboration. 2008. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
4. Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, MackenC, Richman DD, Christopherson C, Borellini F, et al. 2003. Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS 17: 53-63.
5. Apetrei C, Kaur A, Lerche NW, Metzger M, Pandrea I, Hardcastle J, Falkenstein S, Bohm R, Koehler J, Traina-Dorge V, et al. 2005. Molecular epidemiology of simian immunodeficiency virus SIVsm in U. S. primate centers unravels the origin of SIVmac and SIVstm. J Virol 79: 8991-9005.
6. Arron ST, Ribeiro RM, Gettie A, Bohm R, Blanchard J, Yu J, Perelson AS, Ho DD, Zhang L. 2005. Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. Eur J Immunol 35: 46-55.
7. Asquith B, Edwards CT, Lipsitch M, McLean AR. 2006. Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biol 4: e90. doi: 10. 1371/journal. pbio. 0040090.
8. + T cell homeostasis and function in advanced HIV disease. Science 277: 112-116.
9. Baggaley RF, White RG, Boily MC. 2008. Systematic review of orogenital HIV-1 transmission probabilities. Int J Epidemiol 37: 1255-1265.
10. Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, Blankson JN, Siliciano RF. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 80: 4758-4770.
11. + count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 22: 841-848.
12. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, et al. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868-871.
13. Batman PA, Miller AR, Forster SM, Harris JR, Pinching AJ, Griffin GE. 1989. Jejunal enteropathy associated with human immunodeficiency virus infection: Quantitative histology. J Clin Pathol 42: 275-281.
14. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, Larsson M, Gorelick RJ, Lifson JD, Bhardwaj N. 2005. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 115: 3265-3275.
15. Belmonte L, Olmos M, Fanin A, Parodi C, Bare P, Concetti H, Perez H, de BraccoMM, Cahn P. 2007. The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART. AIDS 21: 2106-2108.
16. + T-cell responses: Relationship to viral load in untreated HIV infection. J Virol 75: 11983-11991.
17. + T cells. Blood 107: 4781-4789.
18. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, SilicianoJD, Williams TM, Siliciano RF. 2007. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 81: 2508-2518.
19. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M. 2009. Heterosexual risk of HIV-1 infection per sexual act: Systematic review and meta-analysis of observational studies. Lancet Infect Dis 9: 118-129.
20. + T cells. Blood 101: 2711-2720.
21. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, KuruppuJ, Yazdani J, Migueles SA, Connors M, et al. 2004a. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: Implications for HIV pathogenesis. J Virol 78: 1160-1168.
22. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200: 749-759.
23. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, et al. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
24. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, ScheinbergP, Price DA, Hage CA, Kholi LM, et al. 2008. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112: 2826-2835.
25. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, KaslowR, Buchbinder S, Hoots K, O'Brien SJ. 1999. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage. Science 283: 1748-1752.
26. Chakrabarti LA, Lewin SR, Zhang L, Gettie A, Luckay A, Martin LN, Skulsky E, Ho DD, Cheng-Mayer C, Marx PA. 2000. Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J Virol 74: 1209-1223.
27. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. 2007. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 18: 2968-2974.
28. Chou CS, Ramilo O, Vitetta ES. 1997. Highly purified CD25-resting T cells cannot be infected de novo with HIV-1. Proc Natl Acad Sci 94: 1361-1365.
29. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI, et al. 2008. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 197: 714-720.
30. Clayburgh DR, Shen L, Turner JR. 2004. A porous defense: The leaky epithelial barrier in intestinal disease. Lab Invest 84: 282-291.
31. Cummins AG, LaBrooy JT, Stanley DP, Rowland R, Shearman DJ. 1990. Quantitative histological study of enteropathy associated with HIV infection. Gut 31: 317-321.
32. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
33. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, et al. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270: 988-991.
34. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, GoedertJJ, Buchbinder SP, Vittinghoff E, Gomperts E, et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273: 1856-1862.
35. + T-cell changes independent of viral load. Blood 104: 942-947.
36. + T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection. Blood 109: 2912-2920.
37. Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, Santiago ML, Hebbeler AM, Greene WC. 2010. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 143: 789-801.
38. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, et al. 1998. Changes in thymic function with age and during the treatment of HIV infection. Nature 396: 690-695.
39. Douek DC, Betts MR, Hill BJ, Little SJ, Lempicki R, Metcalf JA, Casazza J, YoderC, Adelsberger JW, Stevens RA, et al. 2001. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol 167: 6663-6668.
40. + T cells. Nature 417: 95-98.
41. + count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-2296.
42. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, DeeksSG. 2008. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 82: 5398-5407.
43. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, HyltonT, Pawlish KS, McNeel TS, et al. 2008. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123: 187-194.
44. Epple HJ, Schneider T, Troeger H, Kunkel D, Allers K, Moos V, Amasheh M, Loddenkemper C, Fromm M, Zeitz M, et al. 2009. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut 58: 220-227.
45. Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, Paiardini M, Barclay GR, Smedley J, Pung R, Oliveira KM, et al. 2010. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog 6: e1001052. doi: 10. 1371/journal. ppat. 1001052.
46. + T cell population with memory rather than naive cells. Antiviral Res 39: 163-173.
47. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, Mold J, Swainson L, Barbour JD, Baskin CR, et al. 2009. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog 5: e1000295. doi: 10. 1371/journal. ppat. 1000295.
48. Ferreira RC, Forsyth LE, Richman PI, Wells C, Spencer J, MacDonald TT. 1990. Changes in the rate of crypt epithelial cell proliferation and mucosal morphology induced by a T-cell-mediated response in human small intestine. Gastroenterol 98: 1255-1263.
49. Field M. 2006. T cell activation alters intestinal structure and function. J Clin Invest 116: 2580-2582.
50. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. 2008. Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 3: e1915. doi: 10. 1371/journal. pone. 0001915.
51. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, PalkerTJ, Redfield R, Oleske J, Safai B, et al. 1984. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500-503.
52. Gao F, Yue L, White AT, Pappas PG, Barchue J, Hanson AP, Greene BM, Sharp PM, Shaw GM, Hahn BH. 1992. Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 358: 495-499.
53. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, et al. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397: 436-441.
54. + T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 79: 2709-2719.
55. George MD, Wehkamp J, Kays RJ, Leutenegger CM, Sabir S, Grishina I, DandekarS, Bevins CL. 2008. In vivo gene expression profiling of human intestinal epithelial cells: Analysis by laser microdissection of formalin fixed tissues. BMC Genomics 9: 209.
56. + T cell levels: Results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 6: 904-912.
57. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, Shih R, Lewis J, Wiley DJ, Phair JP, et al. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179: 859-870.
58. Goedert JJ, Biggar RJ, Weiss SH, Eyster ME, Melbye M, Wilson S, Ginzburg HM, Grossman RJ, DiGioia RA, Sanchez WC, et al. 1986. Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. Science 231: 992-995.
59. Gonzalez-Scarano F, Martin-Garcia J. 2005. The neuropathogenesis of AIDS. Nat Rev Immunol 5: 69-81.
60. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A. 1981. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N Engl J Med 305: 1425-1431.
61. Goulder PJ, Bunce M, Krausa P, McIntyre K, Crowley S, Morgan B, Edwards A, Giangrande P, Phillips RE, McMichael AJ. 1996. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retrov 12: 1691-1698.
62. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. 2006. Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat Med 12: 289-295.
63. Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, Shacklett BL, Flamm J, Wegelin J, Prindiville T, Dandekar S. 2006. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 80: 8236-8247.
64. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, Cavert W, Gebhard K, Staskus K, Zhang Z-Q, et al. 1996. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274: 985-989.
65. + T cells in human immunodeficiency virus/hepatitis C virus coinfected patients. Gut 55: 1484-1487.
66. Hasegawa A, Liu H, Ling B, Borda JT, Alvarez X, Sugimoto C, Vinet-Oliphant H, Kim WK, Williams KC, Ribeiro RM, et al. 2009. The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood 114: 2917-2925.
67. Hasse B, Ledergerber B, Egger M, Vernazza P, Furrer H, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Weber R. 2011. Aging and (non-HIV-associated) co-morbidity in HIV-positive persons: The Swiss HIV cohort study (SHCS). In 18th Conference on Retroviruses and Opportunistic Infections, Abstract O-161. Boston.
68. Haynes BF, Hale LP, Weinhold KJ, Patel DD, Liao HX, Bressler PB, Jones DM, Demarest JF, Gebhard-Mitchell K, Haase AT, et al. 1999. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. J Clin Invest 103: 453-460.
69. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, Hamann D, Prins M, Miedema F. 2003. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17: 1881-1888.
70. Heise C, Vogel P, Miller CJ, Halsted CH, Dandekar S. 1993. Simian immunodeficiency virus infection of the gastrointestinal tract of rhesus macaques: Functional, pathological and morphological changes. Am J Pathol 142: 1759-1771.
71. Heise C, Miller CJ, Lackner A, Dandekar S. 1994. Primary acute simian immunodeficiency virus infection of intestinal lymphoid tissue is associated with gastrointestinal dysfunction. J Infect Dis 169: 1116-1120.
72. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, Markowitz N, Rosen MJ, Mangura BT, Hopewell PC. 1995. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 333: 845-851.
73. Horton H, Vogel T, O'Connor D, Picker L, Watkins DI. 2002. Analysis of the immune response and viral evolution during the acute phase of SIV infection. Vaccine 20: 1927-1932.
74. Hu JJ, Gardner MB, Miller CJ. 2000. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 74: 6087-6095.
75. + T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 197: 126-133.
76. + T cell recovery on antiretroviral therapy. J Infec Dis 203: 1474-1483.
77. + T cells. J Virol 81: 3477-3486.
78. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, Coutinho RA, Eugen-Olsen J, Gallart T, Katzenstein TL, et al. 2001. Effects of CCR5-Δ32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 135: 782-795.
79. James SP, Graeff AS, Zeitz M. 1987. Predominance of helper-inducer T cells in mesenteric lymph nodes and intestinal lamina propria of normal nonhuman primates. Cell Immunol 107: 372-383.
80. Janoff EN, Breiman RF, Daley CL, Hopewell PC. 1992. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 117: 314-324.
81. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, MartinJ, Sinclair E, Asher AI, et al. 2009. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 199: 1177-1185.
82. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. 2011. Increasing burden of liver disease in patients with HIV infection. Lancet 377: 1198-1209.
83. Kalayjian RC, Machekano RN, Rizk N, Robbins GK, Gandhi RT, Rodriguez BA, Pollard RB, Lederman MM, Landay A. 2010. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 201: 1796-1805.
84. Kaslow RA, Duquesnoy R, VanRaden M, Kingsley L, Marrari M, Friedman H, SuS, Saah AJ, Detels R, Phair J, et al. 1990. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet 335: 927-930.
85. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, et al. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 2: 405-411.
86. + T-lymphocyte proliferation and activation in acute simian immunodeficiency virus infection. J Virol 74: 8413-8424.
87. + cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 48: 787-794.
88. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. 1995. Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332: 228-232.
89. Kirk GD, Merlo C, O'Driscoll P, Mehta SH, Galai N, Vlahov D, Samet J, EngelsEA. 2007. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 45: 103-110.
90. Kolls JK, Linden A. 2004. Interleukin-17 family members and inflammation. Immunity 21: 467-476.
91. Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, Eeftinck SchattenkerkJK, Reiss P, Tersmette M, Lange JM, Schuitemaker H. 1999. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 179: 254-258.
92. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, Sereti I, Polis MA, Davey RT, Tavel J, et al. 2001. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med 194: 1731-1741.
93. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, et al. 2008. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203. doi: 10. 1371/journal. pmed. 0050203.
94. Lackner AA. 1994. Pathology of simian immunodeficiency virus induced disease. In Current topics in microbiology and immunology: Simian immunodeficiency virus (ed. Desrosiers RC, Letvin N), pp. 35-64. Springer-Verlag, Berlin.
95. Lackner AA, Vogel P, Ramos RA, Kluge JD, Marthas M. 1994. Early events in tissues during infection with pathogenic (SIVmac239) and nonpathogenic (SIVmac1A11) molecular clones of simian immunodeficiency virus. Am J Pathol 145: 428-439.
96. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. 1983. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 309: 453-458.
97. 3. J Acquir Immune Defic Syndr 44: 179-187.
98. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, et al. 1998. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS clinical trials group protocol 315. J Infect Dis 178: 70-79.
99. Lederman MM, Rodriguez B, Clagett B, Funderburg N, Medvik K, Gripshover B, Kalayjian RC, Sieg S, Calabrese L. 2010. Immune failure after suppressive ART: High level CD4 and CD8 T cell activation but only memory CD4 cells are cycling. In 18th Conference on Retroviruses and Opportunistic infections, Abstract 47LB. Boston.
100. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, Oshiro LS. 1984. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225: 840-842.
101. + T cells. Nature 434: 1148-1152.
102. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203: 2271-2279.
103. Ling B, Apetrei C, Pandrea I, Veazey RS, Lackner AA, Gormus B, Marx PA. 2004. Classic AIDS in a sooty mangabey after an 18 year natural infection. J Virol 78: 8902-8908.
104. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377.
105. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 16: 83-92.
106. +T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 18: 332-340.
107. Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez TS, Yao XJ, Lynch D, Pilon AA, Hawley N, Kim JE, et al. 2003. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 111: 1547-1554.
108. Ma ZM, Abel K, Rourke T, Wang Y, Miller CJ. 2004. A period of transient viremia and occult infection precedes persistent viremia and antiviral immune responses during multiple low-dose intravaginal simian immunodeficiency virus inoculations. J Virol 78: 14048-14052.
109. + T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol 1: 475-488.
110. MacDonald TT, Spencer J. 1988. Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine. J Exp Med 167: 1341-1349.
111. MacDonald TT, Spencer J. 1992. Cell-mediated immune injury in the intestine. Gastroenterol Clin N Am 21: 367-386.
112. MacDonald TT, Spencer J. 1994. Lymphoid cells and tissues of the gastrointestinal tract. In Gastrointestinal and hepatic immunology (ed. HeatleyRH), pp. 1-23. Cambridge University Press, Cambridge.
113. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. 2010. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 467: 214-217.
114. + T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 22: 2035-2038.
115. Marin B, Thiebaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, Hamouda O, Prins M, Walker S, Porter K, et al. 2009. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 23: 1743-1753.
116. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, Buchbinder S, HootsK, Vlahov D, Trowsdale J, et al. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31: 429-434.
117. Martinson JA, Montoya CJ, Usuga X, Ronquillo R, Landay AL, Desai SN. 2010. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell α interferon: Implication for T-cell activation. Antimicrob Agents Chemother 54: 871-881.
118. Marx PA, Li Y, Lerche NW, Sutjipto S, Gettie A, Yee JA, Brotman BH, Prince AM, Hanson A, Webster RG, et al. 1991. Isolation of a simian immunodeficiency virus related to human immunodeficiency virus type 2 from a West African pet sooty mangabey. J Virol 65: 4480-4485.
119. Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA, Holzman RS, WormserG, Brettman L, Lange M, Murray HW, et al. 1981. An outbreak of community-acquired Pneumocystis carinii pneumonia: Initial manifestation of cellular immune dysfunction. N Engl J Med 305: 1431-1438.
120. + T cells in multiple tissues during acute SIV infection. Nature 434: 1093-1097.
121. McGowan I, Elliott J, Fuerst M, Taing P, Boscardin J, Poles M, Anton P. 2004. Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation. J Acquir Immune Defic Syndr 37: 1228-1236.
122. + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200: 761-770.
123. Mehandru S, Poles MA, Tenner-Racz K, Jean-Pierre P, Manuelli V, Lopez P, ShetA, Low A, Mohri H, Boden D, et al. 2006. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 3: e484. doi: 10. 1371/journal. pmed. 0030484.
124. Meier A, Alter G, Frahm N, Sidhu H, Li B, Bagchi A, Teigen N, Streeck H, Stellbrink HJ, Hellman J, et al. 2007. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol 81: 8180-8191.
125. Mellors JW, Rinaldo CR Jr., Gupta P, White RM, Todd JA, Kingsley LA. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167-1170.
126. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954.
127. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3: 1061-1068.
128. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29: 1009-1021.
129. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L, Compton L, Duan L, Shore MD, et al. 2005. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 79: 9217-9227.
130. Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, Pereyra F, TrochaA, Addo MM, Block BL, Rothchild AC, et al. 2008. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: Lack of gross genetic defects or common amino acid changes. J Virol 82: 8422-8430.
131. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, et al. 2010. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 55: 262-270.
132. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, Markowitz M, Kost R, Hurley A, Weinberger L, Cesar D, et al. 2001. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 194: 1277-1287.
133. Moore JP, Kitchen SG, Pugach P, Zack JA. 2004. The CCR5 and CXCR4 coreceptors-Central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retrov 20: 111-126.
134. Mowat AM, Viney JL. 1997. The anatomical basis of intestinal immunity. Immunol Rev 156: 145-166.
135. Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, Brenchley JM, Douek DC. 2010. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 84: 12082-12086.
136. Neutra MR, Frey A, Kraehenbuhl J-P. 1996. Epithelial M cells: Gateways for mucosal infection and immunization. Cell 86: 345-348.
137. + effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med 204: 2171-2185.
138. Olsson J, Poles M, Spetz AL, Elliott J, Hultin L, Giorgi J, Andersson J, Anton P. 2000. Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and β-chemokines. J Infect Dis 182: 1625-1635.
139. + elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS 24: 1095-1105.
140. Palella FJ Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, HolmbergSD. 2006. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 43: 27-34.
141. Pandrea I, Sodora DL, Silvestri G, Apetrei C. 2008. Into the wild: Simian immunodeficiency virus (SIV) infection in natural hosts. Trends Immunol 29: 419-428.
142. Paranjpe S, Craigo J, Patterson B, Ding M, Barroso P, Harrison L, Montelaro R, Gupta P. 2002. Subcompartmentalization of HIV-1 quasispecies between seminal cells and seminal plasma indicates their origin in distinct genital tissues. AIDS Res Hum Retrov 18: 1271-1280.
143. + memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med 200: 1299-1314.
144. Piconi S, Parisotto S, Capetti A, Passerini S, Argenteri B, Terzi R, Meraviglia P, Rizzardini G, Clerici M, Trabattoni D. 2011. Hyperimmune bovine colostrum may decrease plasma levels of microbial products and immune activation in untreated HIV infection. In 18th Conference on Retroviruses and Opportunistic Infections, Abstract 382, Boston.
145. Poles MA, Boscardin WJ, Elliott J, Taing P, Fuerst MM, McGowan I, Brown S, Anton PA. 2006. Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr 43: 65-68.
146. Pope M, Betjes MGH, Romani N, Hirmand H, Cameron PU, Hoffman L, GezelterS, Schuler G, Steinman RM. 1994. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell 78: 389-398.
147. + T cell recovery despite suppressive ART. In 18th Conference on Retroviruses and Opportunistic Infections, Abstract 304. Boston.
148. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, Godinez I, Sankaran S, Paixao TA, Gordon MA, et al. 2008. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotesSalmonella dissemination from the gut. Nat Med 14: 421-428.
149. + and CD25-T cells in acute HIV infection in vitro. J Immunol 150: 5202-5208.
150. Reka S, Garro ML, Kotler DP. 1994. Variation in the expression of human immunodeficiency virus RNA and cytokine mRNA in rectal mucosa during the progression of infection. Lymphokine Cytok Res 13: 391-398.
151. + T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: Too late and too little. J Virol 79: 9228-9235.
152. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, BoswellSL, Mathews WC, Bangsberg DR, Martin J, et al. 2006. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA296: 1498-1506.
153. Ross MJ, Klotman PE. 2004. HIV-associated nephropathy. AIDS 18: 1089-1099.
154. Ryzhova EV, Crino P, Shawyer L, Westmoreland SV, Lackner AA, Gonzalez-Scarano F. 2002. Simian immunodeficiency virus encephalitis: Analysis of envelope sequences from individual brain multinucleated giant cells and tissue samples. Virology 297: 57-67.
155. + T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med 187: 1295-1303.
156. Salkowitz JR, Purvis SF, Meyerson H, Zimmerman P, O'Brien TR, Aledort L, EysterME, Hilgartner M, Kessler C, Konkle BA, et al. 2001. Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol 98: 200-211.
157. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, et al. 1996. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722-725.
158. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, et al. 2011. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780-790.
159. Sankaran S, Guadalupe M, Reay E, George MD, Flamm J, Prindiville T, DandekarS. 2005. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci 102: 9860-9865.
160. Sankaran S, George MD, Reay E, Guadalupe M, Flamm J, Prindiville T, DandekarS. 2008. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol 82: 538-545.
161. Sasseville VG, Du Z, Chalifoux LV, Pauley DR, Young HL, Sehgal PK, DesrosiersRC, Lackner AA. 1996. Induction of lymphocyte proliferation and severe gastrointestinal disease in macaques by a nef gene variant of SIVmac239. Am J Pathol 149: 163-176.
162. Schacker T, Collier AC, Hughes J, Shea T, Corey L. 1996. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 125: 257-264.
163. Schacker TW, Nguyen PL, Beilman GJ, Wolinsky S, Larson M, Reilly C, Haase AT. 2002. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 110: 1133-1139.
164. Schacker TW, Reilly C, Beilman GJ, Taylor J, Skarda D, Krason D, Larson M, Haase AT. 2005. Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS 19: 2169-2171.
165. Schieferdecker HL, Ullrich R, Hirseland H, Zeitz M. 1992. T cell differentiation antigens on lymphocytes in the human intestinal lamina propria. J Immunol 149: 2816-2822.
166. Shanahan F. 1999. Intestinal lymphoepithelial communication. Adv Exp Med Biol 473: 1-9.
167. Shannon RP. 2001. SIV cardiomyopathy in non-human primates. Trends Cardiovasc Med 11: 242-246.
168. Sheth PM, Chege D, Shin LY, Huibner S, Yue FY, Loutfy M, Halpenny R, PersadD, Kovacs C, Chun TW, et al. 2008. Immune reconstitution in the sigmoid colon after long-term HIV therapy. Mucosal Immunol 1: 382-388.
169. Shive C, Lederman MM, Calabrese L, Funderburg N, Bonilla H, Gripshover B, Salata RA, McComsey GA, Clagett B, Medvik K, et al. 2011. Immunologic failure despite suppressive antiretroviral therapy (ART) is related to increased inflammation and evidence of microbial translocation. In 18th Conference on Retroviruses and Opportunistic Infections, Abstract 320. Boston.
170. Sieg SF, Rodriguez B, Asaad R, Jiang W, Bazdar DA, Lederman MM. 2005. Peripheral S-phase T cells in HIV disease have a central memory phenotype and rarely have evidence of recent T cell receptor engagement. J Infect Dis 192: 62-70.
171. Sieg SF, Bazdar DA, Lederman MM. 2008. S-phase entry leads to cell death in circulating T cells from HIV-infected persons. J Leukocyte Biol 83: 1382-1387.
172. Siegal FP, Lopez C, Hammer GS, Brown AE, Kornfeld SJ, Gold J, Hassett J, Hirschman SZ, Cunningham-Rundles C, Adelsberg BR, et al. 1981. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 305: 1439-1444.
173. Silvestri G, Sodora DL, Koup RA, Paiardini M, O'Neil SP, McClure HM, StapransSI, Feinberg MB. 2003. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18: 441-452.
174. Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, Wolinsky SM, Ho DD. 1996. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 183: 215-225.
175. Steinman L. 2007. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13: 139-145.
176. Stevceva L, Kelsall B, Nacsa J, Moniuszko M, Hel Z, Tryniszewska E, FranchiniG. 2002. Cervicovaginal lamina propria lymphocytes: Phenotypic characterization and their importance in cytotoxic T-lymphocyte responses to simian immunodeficiency virus SIVmac251. J Virol 76: 9-18.
177. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. 1990. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 9: 1551-1560.
178. Stone JD, Heise CC, Miller CJ, Halsted CH, Dandekar S. 1994. Development of malabsorption and nutritional complications in simian immunodeficiency virus-infected rhesus macaques. AIDS 8: 1245-1256.
179. Tang J, Costello C, Keet IP, Rivers C, Leblanc S, Karita E, Allen S, Kaslow RA. 1999. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retrov 15: 317-324.
180. ++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS 16: 589-596.
181. Traber PG. 1997. Epithelial cell growth and differentiation. V. Transcriptional regulation, development, and neoplasia of the intestinal epithelium. Am J Physiol 273: G979-G981.
182. + T cells leads to reversible immune dysfunction. Nat Med 12: 1198-1202.
183. Triant VA, Lee H, Hadigan C, Grinspoon SK. 2007. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92: 2506-2512.
184. Turner JR. 2006. Molecular basis of epithelial barrier regulation: From basic mechanisms to clinical application. Am J Pathol 169: 1901-1909.
185. Turner JR. 2009. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9: 799-809.
186. Ullrich R, Zeitz M, Heise W, L'age M, Hoffken G, Riecken EO. 1989. Small intestinal structure and function in patients infected with human immunodeficiency virus (HIV): Evidence for HIV-induced enteropathy. Ann Intern Med 111: 15-21.
187. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. 2010. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 24: 1527-1535.
188. + T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J Infec Dis 187: 769-776.
189. Veazey RS, Rosenzweig M, Shvetz DE, Pauley DR, DeMaria M, Chalifoux LV, Johnson RP, Lackner AA. 1997. Characterization of gut-associated lymphoid tissue (GALT) of normal rhesus macaques. Clin Immunol Immunopathol 82: 230-242.
190. + T cell depletion and viral replication in SIV infection. Science 280: 427-431.
191. + T cells in lymphoid tissues during SIV infection. J Virol 74: 11001-11007.
192. + T cells are rapidly eliminated in early SIV infection in vivo. J Virol 74: 57-64.
193. + T cells in the intestine of macaques during primary infection. J Virol 75: 10515-10519.
194. Veazey RS, Marx PA, Lackner AA. 2001b. The mucosal immune system: Primary target for HIV infection and fundamental component of AIDS pathogenesis. Trends Immunol 22: 626-633.
195. + T cells in AIDS pathogenesis. Trends Immunol 23: 129.
196. Veazey RS, Lifson JD, Schmitz JE, Kuroda MJ, Piatak M, Pandrea I, Purcell J, Bohm R, Blanchard J, Williams KC, et al. 2003. Dynamics of simian immunodeficiency virus-specific cytotoxic T-cell responses in tissues. J Med Primatol 32: 194-200.
197. Viney J, MacDonald TT, Spencer J. 1990. γ/δ T cells in the gut epithelium. Gut 31: 841-844.
198. Weber CR, Turner JR. 2007. Inflammatory bowel disease: Is it really just another break in the wall? Gut 56: 6-8.
199. Weber R, Friis-Moller N, Sabin C, Reiss P, Monforte A, Dabis F, El-Sadr WM, De Wit S, Morfeldt L, Law M, et al. 2005. HIV and non-HIV-related deaths and their relationship to immunodeficiency: The D: A: D study. In 12th Conference on Retroviruses and Opportunistic Infections, Abstract 595. Boston.
200. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, LawMG, Pradier C, De Wit S, et al. 2006. Liver-related deaths in persons infected with the human immunodeficiency virus: The D: A: D study. Arch Intern Med 166: 1632-1641.
201. Westmoreland SV, Halpern E, Lackner AA. 1998. Simian immunodeficiency virus encephalitis in rhesus macaques is associated with rapid disease progression. J Neurovirol 4: 260-268.
202. + adolescent population. AIDS Res Hum Retrov 20: 263-269.
203. Woelk CH, Ottones F, Plotkin CR, Du P, Royer CD, Rought SE, Lozach J, Sasik R, Kornbluth RS, Richman DD, et al. 2004. Interferon gene expression following HIV type 1 infection of monocyte-derived macrophages. AIDS Res Hum Retrov 20: 1210-1222.
204. Wykrzykowska JJ, Rosenzweig M, Veazey RS, Simon MA, Halvorsen K, Desrosiers RC, Johnson RP, Lackner AA. 1998. Early regeneration of thymic progenitors in rhesus macaques infected with simian immunodeficiency virus. J Exp Med 187: 1767-1778.
205. Yadavalli GK, Lederman MM, Sieg S, Funderburg N, Clagett B, Medvik K, SalataRA, Gripshover B, Fulton S, Rodriguez B. 2011. Hyperimmune bovine colostrum may decrease plasma levels of microbial products and immune activation in untreated HIV infection. In 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Abstract 3842. Rome.
206. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. 2010. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 11: 1005-1013.
207. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. 1990. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 61: 213-222.
208. Zagury D, Bernard J, Leonard R, Cheynier R, Feldman M, Sarin PS, Gallo RC. 1986. Long-term cultures of HTLV-III-infected T cells: A model of cytopathology of T-cell depletion in AIDS. Science 231: 850-853.
209. Zeitz M, Greene WC, Peffer NJ, James SP. 1988. Lymphocytes isolated from the intestinal lamina propria of normal nonhuman primates have increased expression of genes associated with T-cell activation. Gastroenterol 94: 647-655.